Johnson & Johnson Q2 2026 Earnings: Beat and Raise, But Shares Slip on MedTech Miss
The company raised full-year guidance and remains on track for its first $100 billion revenue year.
/ 57 items
#XY Earnings Movers↓
Elevance Health Reports Strong Q2 Beat but Shares Slide on Rising Medical Costs and Lower Margins
Despite beating Q2 estimates and lifting 2026 guidance, Elevance Health saw margins compress sharply. Core operating margin fell to 3.5% on higher medical costs.
HCA Healthcare Cuts 2026 Earnings Guidance as Uninsured Patient Surge Weighs on Profits
$400M pre-tax hit in Q2 as ACA subsidies expire.
enGene Lays Off 50% of Staff and Stops Patient Enrollment to Save Cash
enGene is reducing its workforce by ~50% and has stopped patient enrollment in three additional LEGEND trial cohorts to preserve cash while focusing on its pivotal data and planned BLA filing.
REGENXBIO Q1 Earnings: Revenue Miss Overshadows Positive Duchenne Gene Therapy Data
Regenxbio’s DMD gene therapy showed strong results, boosting muscle protein and safety, moving closer to FDA approval.
Hims & Hers Q1 2026 Earnings: Big Subscriber Jump But Misses Estimates – Raises Full-Year Outlook
Hims & Hers missed earnings, lost money, but grew users and expects stronger future growth with higher revenue guidance.